


CLAIMS

What I claim is:


1. A method of adjuvant chemotherapy in human patients with stage I or II breast cancer, which comprises, following surgical removal of tumor:
 - (a) first administering to said patients at least one diphenyl compound of the formula:



wherein X and Y are each fluorine, chlorine or bromine, Z is an alkylene group of 1 to 3 carbon atoms or =C=O, or the phenyl groups are joined to form a tricyclic ring, o and p are 0 or 1, R₁ and R₂ are an alkyl each group containing 1 to 3 carbon atoms or are joined together to form a heterocyclic ring with the nitrogen atom and n is 1, 2 or 3, or pharmaceutically-acceptable salts thereof, and


- (b) following sufficient time to permit inhibition of binding of intracellular histamine, subsequently administering to the patient a chemotherapeutic agent active in breast cancer.

2. The method of claim 1 wherein the group



is a diethylamino group, a dimethylamino group, a morpholino group or a piperazino group.

3. The method of claim 1 wherein the group



is a diethylamino group, Z is -CH₂, n is 2 and o and p are each 0.

4. The method of claim 3 wherein diphenyl compound is in the form of a hydrochloride salt or free base.
5. The method of claim 1 wherein said chemotherapeutic agent active in breast cancer is doxorubicin.
6. The method of claim 4 wherein said chemotherapeutic agent active in breast cancer is doxorubicin or epirubicin alone or in combination with taxanes (Taxol or Taxotere).
7. The method of claim 1 wherein said diphenyl compound is administered to the patient about 30 to about 90 minutes prior to said administration of said chemotherapeutic agent.
8. The method of claim 7 wherein said time is about 60 minutes.
9. The method of claim 6 wherein said diphenyl compound is administered by intravenous infusion of a solution thereof over a period of time of up to about 90 minutes prior to administration of said chemotherapeutic agent and is maintained during administration of said chemotherapeutic agent.
10. The method of claim 9 wherein said diphenyl compound is administered for about 60 minutes prior to administration of said chemotherapeutic agent and is maintained during about 20 minutes intravenous infusion of said chemotherapeutic agent.
11. The method of claim 7 wherein said diphenyl compound is administered in an amount of about 8 to about 240 mg/M² of said patient.
12. The method of claim 11 wherein said amount is about 3 to about 10 mg/kg of patient.
13. The method of claim 9 wherein said diphenyl compound is administered in an amount of about 3 to about 10 mg/kg of patient.
14. The method of claim 10 wherein said diphenyl compound is administered in an amount of about 6 mg/kg in the form of the hydrochloride salt or 5.3 mg/kg in the form of the free base.
15. The method of claim 11 wherein said chemotherapeutic agent is administered in an amount of about 50 to about 75 mg/M² of patient for doxorubicin or epirubicin, about 175 to about 225 mg/M² for Taxol and about 75 to about 100 mg/M² for Taxotere.

16. The method of claim 14 wherein said chemotherapeutic agent is administered in an amount of about 60 mg/M² of patient.

17. The method of claim 1 wherein said patients with stage I or II breast cancer are patients who have received no prior chemotherapy treatment.

18. The method of claim 1 wherein said patients with stage I or II breast cancer are patients who have received no prior treatment type.


19. The method of claim 1 wherein the human patients with stage I or II breast cancer are patients with estrogen receptor-negative tumors.

20. A method of achieving enhanced survival in human patients with stage I or II breast cancer, which comprises:

(a) selecting for chemotherapy treatment patients who have had no prior chemotherapy treatment or any previous treatment type or estrogen receptor-negative tumors, and

(b) subject said selected patients to chemotherapy treatment for a plurality of cycles at predetermined intervals, each said cycle comprising:

(i) first administering to said selected patients at least one diphenyl compound of the formula:



wherein X and Y are each fluorine, chlorine or bromine, Z is an alkylene group of 1 to 3 carbon atoms or =C=O, or the phenyl groups are joined to form a tricyclic ring, o and p are 0 or 1, R₁ and R₂ are each an alkyl group containing 1 to 3 carbon atoms or are joined together to form a heterocyclic ring with the nitrogen atom and n is 1, 2 or 3, or pharmaceutically-acceptable salts thereof, and

(ii) following sufficient time to permit inhibition of binding of intracellular histamine, subsequently administering to the patient a chemotherapeutic agent active in breast cancer.

21. The method claimed in claim 20, wherein said selected patients are treated for about 4 to about 6 cycles and predetermined intervals of about 21 to about 28 days.